Agilent Technologies Operating Income decreased by 20.3% to $353.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.1%, from $376.00M to $353.00M. Over 4 years (FY 2021 to FY 2025), Operating Income shows relatively stable performance with a 2.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Growth in operating income suggests that the core business is becoming more profitable and efficient.
The profit realized from a business's own operations after deducting operating expenses like wages, depreciation, and co...
This is a key metric for comparing the fundamental business performance of companies with different tax or debt structures.
operating_income| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $288.00M | $336.00M | $395.00M | $376.00M | $360.00M | $411.00M | $471.00M | $426.00M | $383.00M | $133.00M | $408.00M | $384.00M | $363.00M | $333.00M | $408.00M | $376.00M | $300.00M | $360.00M | $443.00M | $353.00M |
| QoQ Change | — | +16.7% | +17.6% | -4.8% | -4.3% | +14.2% | +14.6% | -9.6% | -10.1% | -65.3% | +206.8% | -5.9% | -5.5% | -8.3% | +22.5% | -7.8% | -20.2% | +20.0% | +23.1% | -20.3% |
| YoY Change | — | — | — | — | +25.0% | +22.3% | +19.2% | +13.3% | +6.4% | -67.6% | -13.4% | -9.9% | -5.2% | +150.4% | +0.0% | -2.1% | -17.4% | +8.1% | +8.6% | -6.1% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Agilent CrossLab | $123.00M | $140.00M | $139.00M | $221.00M | $231.00M | $248.00M | $246.00M | $240.00M |
| Life Sciences and Diagnostics Markets | — | — | — | $117.00M | $129.00M | $118.00M | $172.00M | $109.00M |
| Applied Markets | — | — | — | $84.00M | $59.00M | $71.00M | $87.00M | $93.00M |
| Diagnostics and Genomics | $86.00M | $70.00M | $94.00M | — | — | — | — | — |
| Life Sciences and Applied Markets | $186.00M | $222.00M | $233.00M | — | — | — | — | — |
| Total | $363.00M | $333.00M | $408.00M | $376.00M | $300.00M | $360.00M | $443.00M | $353.00M |